FibroGen (FGEN) Appoints David DeLucia as CFO

FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.

Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury.

“Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabilities required to lead our finance organization and be a key member of our leadership team,” said Thane Wettig, Chief Executive Officer of FibroGen. “His deep understanding of all aspects of our business, along with his proven track record and strategic insights will be invaluable in his new role as CFO as we advance FG-3246, a first-in-class ADC targeting CD46, and its companion diagnostic FG-3180, while further building on the strong performance of roxadustat.”

“I am thrilled to take on the role of CFO at FibroGen and to help lead the company at this important time,” said DeLucia. “With our recent transformation into a lean and focused organization, I believe we are well positioned for an exciting future and look forward to continued execution on our strategic vision to bring novel therapies forward for cancer and cancer-related conditions.”

Mr. DeLucia has nearly 15 years of financial leadership and experience within the life sciences industry. Prior to joining FibroGen in 2022, he held positions of increasing responsibility at TherapeuticsMD, overseeing Financial Planning and Analysis, Corporate Development, and Investor Relations. Earlier in his career, he was a buy-side investor at JP Morgan Asset Management, covering small and mid-cap healthcare companies.

Mr. DeLucia holds the Chartered Financial Analyst® designation and a dual degree of Bachelor of Business Administration in Finance & Accounting and Bachelor of Science in Economics from the University of Michigan - Stephen M. Ross School of Business.

You May Also Be Interested In

• Baxter raises tender offer cap to $600M for senior notes
• JPMorgan Downgrades Cogent Communications (CCOI) to Underweight
• Infleqtion plans 2027 quantum sensing field test in Colorado